Patients who took Femara for five years had 19% fewer breast cancer recurrences than those who took Tamoxifen, the current gold standard.

FORBES: Cancer Drugs On The Way, But Who Pays?

On Friday the drug was approved for use in combination with Aromasin for postmenopausal women with recurring HER2-negative breast cancer, after treatment with the drugs Femara and Arimidex.

MSN: FDA approves Afinitor for some breast cancers

At Friday's press briefing, data are being presented from a five-year, 8, 000-patient study of Novartis' pill Femara, which is used to keep breast cancer from recurring after chemotherapy and surgery.

FORBES: Magazine Article